IP Library Granted Patent US 12,195,792
Granted Patent B2
US 12,195,792 · App. 16/074,593 · Granted Jan 14, 2025

Dried amplification compositions

Inventors: Steven Mauch (San Diego, CA); Robert Stephen Dickson (San Diego, CA); Matthias Jost (San Diego, CA); Mark Filipowsky (San Marcos, CA); Donald Martin (Escondido, CA); Vladislav Nodelman (San Diego, CA); Cheryl Lynn Crowell (San Diego, CA)
Assignee: GEN-PROBE INCORPORATED
C12Q1/686C12Q1/6804
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,792
App. No.
16/074,593
Granted
Jan 14, 2025
Kind
B2
Abstract

The disclosure provides dried compositions providing reagents for nucleic acid amplification, which are essentially free of inorganic salts. Lack of inorganic salts increases stability of such compositions and decreases formation of byproducts. Salts required for use of enzymes in the composition are supplied on reconstitution.

Claims (17)

1. A composition comprising an aqueous solution containing a reverse transcriptase, another polymerase, a bulking agent consisting essentially of trehalose at a concentration from about 0.16 M to about 0.32 M, a detergent, an organic buffer, from 0.1 mM to 0.3 mM of dATP, from 0.1 mM to 0.3 mM of dGTP, from 0.1 mM to 0.3 mM of dCTP, from 0.2 mM to 0.6 mM of dTTP or dUTP, RNase inhibitor and at least two oligonucleotides useful for performing a molecular assay, wherein the aqueous solution has a concentration of Mg 2+ of less than 0.1 mM and a concentration of K + of less than 1 mM.

2. The composition of claim 1 , wherein the at least two oligonucleotides are selected from the group consisting of: an amplification oligonucleotide, a detection probe oligonucleotide, a target capture probe oligonucleotide, an adaptor oligonucleotide, and combinations thereof.

3. The composition of claim 1 , wherein the aqueous solution comprises an inorganic salt concentration of 1 mM or less.

4. The composition of claim 1 , wherein the aqueous solution comprises a mass per microliter of inorganic salt from about 0.075 μg/μl to about 0.058 μg/μl and wherein the aqueous solution comprises a mass per microliter of chloride ions from about 0.071 μg/μl to about 0.018 μg/μl.

5. The composition of claim 3 , wherein the inorganic salt concentration of the aqueous solution is less than 1 mM sodium chloride.

6. The composition of claim 1 , wherein the other polymerase is present in the aqueous solution at a concentration from about 0.20 U/μl to about 0.72 U/μl in the aqueous solution.

7. The composition of claim 6 , wherein the other polymerase is present in the aqueous solution at a concentration selected from: 0.25 U/μl, 0.30 U/μl, 0.32 U/μl, 0.4 U/μl, 0.5 U/μl, 0.45 U/μl, and 0.72 U/μl.

8. The composition of claim 1 , wherein the reverse transcriptase is present in the aqueous solution at a concentration from about 0.1 U/μl to about 0.6 U/μl.

9. The composition of claim 1 , wherein the RNase inhibitor is at a concentration from about 0.12 U/μl to about 0.20 U/μl.

10. The composition of claim 1 , wherein the aqueous solution further comprises a chelating agent.

11. The composition of claim 10 , wherein the chelating agent is EDTA and is present in the aqueous solution at a concentration from 1.5 mM to 2.0 mM.

12. The composition of claim 1 containing no magnesium ions.

13. A dried composition made by drying a composition comprising an aqueous solution containing a reverse transcriptase, another polymerase, a bulking agent consisting essentially of trehalose at a concentration from about 0.16 M to about 0.32 M, a detergent, an organic buffer, from 0.1 mM to 0.3 mM of dATP, from 0.1 mM to 0.3 mM of dGTP, from 0.1 mM to 0.3 mM of dCTP, from 0.2 mM to 0.6 mM of dTTP or dUTP, RNase inhibitor and at least two oligonucleotides useful for performing a molecular assay, wherein the aqueous solution has a concentration of Mg 2+ of less than 0.1 mM and a concentration of K + of less than 1 mM.

14. A method of forming a mixture for use in performing a nucleic acid based amplification reaction, the method comprising combining a reconstitution solution and the dried composition of claim 13 , wherein the reconstitution solution comprises at least one inorganic salt.

15. The method of claim 14 , wherein the reconstitution solution comprises MgCl 2 at a concentration from about 3.8 mM to about 4.4 mM, KCl at a concentration from about 50 mM to about 80 mM, or both.

16. The method of claim 15 , wherein the reconstitution solution comprises, methyl paraben at a concentration from about 0.012% w/v to about 0.020% w/v, propyl paraben at a concentration from about 0.006% w/v to about 0.010% w/v, absolute ethanol at a concentration from about 0.20% v/v to about 0.30% v/v, or a combination thereof.

17. The method of claim 16 , wherein the concentration of the methyl paraben in the reconstitution solution is 0.016% w/v, the concentration of the propyl paraben in the reconstitution solution is 0.008% w/v and the concentration of the absolute ethanol is present in the reconstitution solution at about 0.26% v/v.

Assignments (3)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2018
From: JOST, MATTHIAS; FILIPOWSKY, MARK; NODELMAN, VLADISLAV; DICKSON, ROBERT STEPHEN; CROWELL, CHERYL LYNN; MAUCH, STEVEN; MARTIN, DONALD
To: GEN-PROBE INCORPORATED
Reel/Frame 047373/0311 →
SECURITY INTEREST Recorded Oct 19, 2018
From: HOLOGIC, INC.; GEN-PROBE INCORPORATED; CYNOSURE, INC.; FAXITRON BIOPTICS, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 047272/0347 →
Continuity (2)
Provisional Application 62291770 · Feb 5, 2016
Related Publication 20190284604A1 · Sep 19, 2019
References Cited (51)
US 5102788A · Cole · 1992 [cited by applicant]
US 5556771A · Shen et al. · 1996 [cited by applicant]
US 5593824A · Treml et al. · 1997 [cited by applicant]
US 5861251A · Park et al. · 1999 [cited by applicant]
US 5876992A · De Rosier et al. · 1999 [cited by applicant]
US 6153412A · Park et al. · 2000 [cited by applicant]
US RE37872E · Franks et al. · 2002 [cited by applicant]
US 6684524B1 · Sennhenn et al. · 2004 [cited by applicant]
US 6908759B2 · Jang · 2005 [cited by applicant]
US 6910720B2 · Shimei · 2005 [cited by examiner]
US 7964350B1 · Fekete · 2011 [cited by examiner]
US 8187557B2 · Van Atta et al. · 2012 [cited by applicant]
US 8426134B2 · Piepenburg et al. · 2013 [cited by applicant]
US 8470261B2 · Eshoo et al. · 2013 [cited by applicant]
US 8900525B2 · Ponaka et al. · 2014 [cited by applicant]
US 20040235138A1 · Weisburg · 2004 [cited by examiner]
US 20050069898A1 · Moon et al. · 2005 [cited by applicant]
US 20060068398A1 · McMillan · 2006 [cited by applicant]
US 20070259348A1 · Phadke · 2007 [cited by examiner]
US 20120135394A1 · Kim · 2012 [cited by examiner]
US 20140011184A1 · DeCastro · 2014 [cited by examiner]
US 20140295419A1 · Zhang · 2014 [cited by examiner]
US 20160032269A1 · Gong · 2016 [cited by examiner]
EP 726310B1 · 2003 [cited by examiner]
EP 1374827A2 · 2004 [cited by applicant]
JP 10503383A · 1998 [cited by applicant]
JP 2007252270A · 2007 [cited by applicant]
WO 2006003439A2 · 2006 [cited by applicant]
WO 2006119280A2 · 2006 [cited by applicant]
WO 2007005626A1 · 2007 [cited by applicant]
WO 2008090340A2 · 2008 [cited by applicant]
WO WO2008155524A1 · 2008 [cited by applicant]
WO WO2010001162A1 · 2010 [cited by examiner]
WO 2010141940A1 · 2010 [cited by applicant]
WO 2010144682A1 · 2010 [cited by applicant]
WO WO2013101783A2 · 2013 [cited by applicant]
WO 2014114956A1 · 2014 [cited by applicant]
WO WO2016034892A1 · 2016 [cited by examiner]
WO 2017136782A1 · 2017 [cited by applicant]
PCT International Search Report, International Application No. PCT/US2017/016592, Apr. 3, 2017. [cited by applicant]
PCT Written Opinion, International Application No. PCT/US2017/016592, Apr. 3, 2017. [cited by applicant]
UKIPO Combined Search and Examination Report under Sections 17 and 18(3), U.K. Application No. GB1701910.0, Dec. 5, 2017. [cited by applicant]
BD Sprint Advantage 96 Plate, Versatile PCR enzyme mix in a high-throughput format, BD Biosciences Clontech, 2002. [cited by applicant]
BD Sprint Advantage PCR Products User Manual, BD Biosciences Clontech, 2003, pp. 1-22. [cited by applicant]
GE Healthcare, “Illustra puReTaq Ready-To-Go PCR Beads”, (Product Booklet) 2006, pp. 1-22. [cited by applicant]
Richards et al., “Thermal stability landscape for Klenow DNA Ploymerase as a function of pH and salt concentration,” Biochimica et aBiophysica Acta 1764, 2006, pp. 1546-1552. [cited by applicant]
Li et al., “The protective effects of trehalose o freeze-drying and LAMP reagents storage,” Progress In Fishery Sciences, vol. 33, No. 5, p. 95-101, (Oct. 2012), English Abstract. [cited by applicant]
Fu et al., “Pharmaceutical Excipients,” China Press of Traditional Chinese Medicine, pp. 110-113, (Oct. 2008), see IDS transmittal for brief statement of relevance. [cited by applicant]
EP 23203507.1 Extended European Search Report mailed Feb. 22, 2024. [cited by applicant]
Lorenz, “Polymerase Chain Reaction: Basic Protocol Plus Troubleshooting and Optimization Strategies,” J. Vis. Exp., (63), e3998, doi:10.279/3998, (2012). [cited by applicant]
KR 10-2018-7022388 Notice of Preliminary Rejection dated Jan. 20, 2024, English translation. [cited by applicant]